• Profile
Close

Metformin add-on vs antipsychotic switch vs continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: Results from the IMPACT trial

World Psychiatry Jan 16, 2020

Correll CU, Sikich L, Reeves G, et al. - Researchers sought to examine the efficacy and tolerability of the addition of metformin, the switch to an antipsychotic with lower risk for weight gain, and continued antipsychotic treatment, against the background of healthy lifestyle education (HLE), in youth with severe mental illness and clinically significant antipsychotic-induced weight gain. In the Improving Metabolic Parameters in Antipsychotic Child Treatment (IMPACT), a randomized, parallel group, 24-week clinical trial, enrollment of overweight/obese, psychiatrically stable youth, aged 8-19 years, with a DSM-IV diagnosis of severe mental illness (schizophrenia spectrum disorder, bipolar spectrum disorder or psychotic depression), was done at four US universities. Treatment with a second-generation antipsychotic led to substantial weight gain in all of them. Researchers here randomized 127 participants via the centralized, computer-based randomization system to unmasked treatment groups: metformin (MET); antipsychotic switch (aripiprazole or, if already exposed to that drug, perphenazine or molindone; SWITCH); or continued baseline antipsychotic (CONTROL). All participants received healthy lifestyle education. Forty-nine participants were randomized to MET, 31 to SWITCH, and 47 to CONTROL. Outcomes revealed the achievement of superior weight-related outcomes for both MET and SWITCH when compared with CONTROL, with effect sizes ranging from 0.40 to 0.99, without being different from one another. Data suggest that adding metformin or switching to a lower risk antipsychotic could lead to pediatric antipsychotic-related overweight/obesity. They identified healthy lifestyle education as insufficient to limit ongoing BMI z-score increase.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay